Genes
Oligo Pools
NGS
Variant Libraries
Antibodies
IVDR Solutions
Webinar
Twist Bioscience HQ
681 Gateway Blvd
South San Francisco, CA 94080
Achieving large-scale antibody affinity maturation
By Melina Mathur, Product Manager for Biopharma at Twist Bioscience.
Antibody optimisation is a game of numbers, and the human body is an excellent player. B lymphocytes develop a diverse catalog of antibodies, with each new iteration giving the body one more chance to recognise and better defend against foreign pathogens.
Thus far, no technology has matched the human immune system’s ability to churn out high-affinity antibodies. However, advances in synthetic antibody engineering, like Twist Biopharma’s Antibody Optimization platform (TAO), are bringing us closer to exposing new possibilities for therapeutic development.
Covered in this Article
How researchers improved a low-affinity anti-PD-1 antibody by creating variants with 50–100x stronger affinity in four months.
How to quickly humanize and optimize low-affinity antibodies to accelerate therapeutic antibody development and help bring effecti
A turning point in synthetic antibody engineering through scale, precision, and the ability to avoid unnatural antibody sequences.
Share your details to Get the Article
